HK1205114A1 - Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents - Google Patents
Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents Download PDFInfo
- Publication number
- HK1205114A1 HK1205114A1 HK15105599.7A HK15105599A HK1205114A1 HK 1205114 A1 HK1205114 A1 HK 1205114A1 HK 15105599 A HK15105599 A HK 15105599A HK 1205114 A1 HK1205114 A1 HK 1205114A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- spiro
- therapeutic agents
- compounds useful
- asymmetric syntheses
- oxindole compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623336P | 2012-04-12 | 2012-04-12 | |
| US61/623,336 | 2012-04-12 | ||
| PCT/US2013/030219 WO2013154712A1 (en) | 2012-04-12 | 2013-03-11 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1205114A1 true HK1205114A1 (en) | 2015-12-11 |
Family
ID=47902379
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15105599.7A HK1205114A1 (en) | 2012-04-12 | 2013-03-11 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
| HK15105598.8A HK1205113A1 (en) | 2012-04-12 | 2013-03-11 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
| HK16114577.4A HK1226389A1 (zh) | 2012-04-12 | 2015-06-12 | 用作治疗剂的螺-羟吲哚化合物的不对称合成 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15105598.8A HK1205113A1 (en) | 2012-04-12 | 2013-03-11 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
| HK16114577.4A HK1226389A1 (zh) | 2012-04-12 | 2015-06-12 | 用作治疗剂的螺-羟吲哚化合物的不对称合成 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9487535B2 (enExample) |
| EP (1) | EP2838902B1 (enExample) |
| JP (1) | JP6195609B2 (enExample) |
| KR (1) | KR20150002794A (enExample) |
| CN (2) | CN105753877A (enExample) |
| AU (1) | AU2013246485A1 (enExample) |
| CA (1) | CA2869547A1 (enExample) |
| EA (1) | EA201491854A1 (enExample) |
| ES (1) | ES2714314T3 (enExample) |
| HK (3) | HK1205114A1 (enExample) |
| IL (1) | IL235006A0 (enExample) |
| MX (1) | MX2014012266A (enExample) |
| WO (1) | WO2013154712A1 (enExample) |
| ZA (1) | ZA201407334B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3032B1 (ar) | 2008-10-17 | 2016-09-05 | Xenon Pharmaceuticals Inc | مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية. |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| KR20120099429A (ko) | 2009-10-14 | 2012-09-10 | 제논 파마슈티칼스 인크. | 스피로-옥스인돌 화합물의 합성 방법 |
| WO2011106729A2 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| HK1205114A1 (en) | 2012-04-12 | 2015-12-11 | Xenon Pharmaceuticals Inc. | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
| WO2016109795A1 (en) | 2014-12-31 | 2016-07-07 | Concert Pharmaceuticals, Inc. | Deuterated funapide and difluorofunapide |
| WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
| WO2017180248A1 (en) * | 2016-04-15 | 2017-10-19 | William Marsh Rice University | Enantioenriched viridicatumtoxin b analogs |
| WO2017214442A1 (en) | 2016-06-08 | 2017-12-14 | President And Fellows Of Harvard College | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome |
| JP2019518058A (ja) * | 2016-06-16 | 2019-06-27 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | スピロ−オキシインドール化合物の固体状態形 |
| US10100060B2 (en) | 2016-06-16 | 2018-10-16 | Xenon Pharmaceuticals Inc. | Asymmetric synthesis of funapide |
| CN108395438A (zh) * | 2018-04-03 | 2018-08-14 | 陕西科技大学 | 一类具有抗菌活性的靛红母核螺环化合物及其合成方法 |
| US12252457B2 (en) | 2018-05-22 | 2025-03-18 | President And Fellows Of Harvard College | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment |
| EP3801512A4 (en) | 2018-05-29 | 2022-01-19 | President and Fellows of Harvard College | COMPOSITIONS AND METHODS TO REDUCE TACTILE DYSFUNCTION, ANXIETY AND SOCIAL DISABILITIES |
| US12077512B2 (en) | 2019-03-25 | 2024-09-03 | President And Fellows Of Harvard College | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment |
| US11345681B1 (en) | 2020-06-05 | 2022-05-31 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| US12552808B2 (en) | 2020-09-03 | 2026-02-17 | Amgen Inc. | Diol desymmetrization by nucleophilic aromatic substitution |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3723459A (en) | 1971-04-23 | 1973-03-27 | Mc Neil Labor Inc | 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives |
| JPS6130554A (ja) | 1984-07-23 | 1986-02-12 | Ono Pharmaceut Co Ltd | プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤 |
| DE3608088C2 (de) | 1986-03-07 | 1995-11-16 | Schering Ag | Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten |
| IL87116A (en) | 1987-07-17 | 1993-03-15 | Schering Ag | 9-halogen-(z)-prostaglandin derivatives and pharmaceutical compositions containing the same |
| US5314685A (en) | 1992-05-11 | 1994-05-24 | Agouron Pharmaceuticals, Inc. | Anhydrous formulations for administering lipophilic agents |
| NO317155B1 (no) | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
| JP4044967B2 (ja) | 1997-02-10 | 2008-02-06 | 小野薬品工業株式会社 | １１，１５−ｏ−ジアルキルプロスタグランジンｅ誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
| DE69821987T2 (de) | 1997-12-25 | 2004-12-16 | Ono Pharmaceutical Co. Ltd. | Omega-cycloalkyl-prostaglandin e2 derivate |
| JP4087938B2 (ja) | 1998-02-04 | 2008-05-21 | 高砂香料工業株式会社 | ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物 |
| US6235780B1 (en) | 1998-07-21 | 2001-05-22 | Ono Pharmaceutical Co., Ltd. | ω-cycloalkyl-prostaglandin E1 derivatives |
| SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| JPWO2005035498A1 (ja) | 2003-10-08 | 2006-12-21 | 住友製薬株式会社 | 含窒素二環性化合物の摂食調節剤としての用途 |
| BRPI0510719A (pt) | 2004-05-05 | 2007-11-20 | Unibioscreen Sa | derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos |
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| AR056968A1 (es) | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | Compuestos espiro-oxindol y composiciones farmacéuticas |
| CN101300012B (zh) | 2005-09-01 | 2011-09-14 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物在制备治疗呼吸系统疾病的药物中的应用 |
| WO2007081895A2 (en) * | 2006-01-09 | 2007-07-19 | Merck & Co., Inc. | Preparation of substituted 2-hydroxygibba-1(10a), 2, 4, 4b-tetraen-6-ones |
| US20110294842A9 (en) | 2006-10-12 | 2011-12-01 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| WO2008060789A2 (en) | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| AU2007307635A1 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| WO2008046087A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro compounds and their uses as therapeutic agents |
| GB0704846D0 (en) | 2007-03-13 | 2007-04-18 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| CA2741024A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| JO3032B1 (ar) | 2008-10-17 | 2016-09-05 | Xenon Pharmaceuticals Inc | مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية. |
| WO2010078307A1 (en) | 2008-12-29 | 2010-07-08 | Xenon Pharmaceuticals Inc. | Spiro-oxindole-derivatives as sodium channel blockers |
| US8295257B2 (en) | 2009-03-13 | 2012-10-23 | Telcordia Technologies, Inc. | Scalable disruptive-resistant communication method |
| WO2010132352A2 (en) * | 2009-05-11 | 2010-11-18 | Xenon Pharmaceuticals Inc. | Spiro compounds and their use as therapeutic agents |
| AR077252A1 (es) * | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| KR20120099429A (ko) | 2009-10-14 | 2012-09-10 | 제논 파마슈티칼스 인크. | 스피로-옥스인돌 화합물의 합성 방법 |
| US20110086899A1 (en) | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| WO2011106729A2 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| HK1205114A1 (en) | 2012-04-12 | 2015-12-11 | Xenon Pharmaceuticals Inc. | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
-
2013
- 2013-03-11 HK HK15105599.7A patent/HK1205114A1/xx unknown
- 2013-03-11 HK HK15105598.8A patent/HK1205113A1/xx unknown
- 2013-03-11 KR KR1020147031580A patent/KR20150002794A/ko not_active Withdrawn
- 2013-03-11 ES ES13710961T patent/ES2714314T3/es active Active
- 2013-03-11 CN CN201610207838.7A patent/CN105753877A/zh active Pending
- 2013-03-11 MX MX2014012266A patent/MX2014012266A/es unknown
- 2013-03-11 EP EP13710961.7A patent/EP2838902B1/en active Active
- 2013-03-11 US US13/794,147 patent/US9487535B2/en active Active
- 2013-03-11 WO PCT/US2013/030219 patent/WO2013154712A1/en not_active Ceased
- 2013-03-11 JP JP2015505723A patent/JP6195609B2/ja active Active
- 2013-03-11 CN CN201380030552.0A patent/CN104350057A/zh active Pending
- 2013-03-11 CA CA2869547A patent/CA2869547A1/en active Pending
- 2013-03-11 AU AU2013246485A patent/AU2013246485A1/en not_active Abandoned
- 2013-03-11 EA EA201491854A patent/EA201491854A1/ru unknown
-
2014
- 2014-10-06 IL IL235006A patent/IL235006A0/en unknown
- 2014-10-09 ZA ZA2014/07334A patent/ZA201407334B/en unknown
-
2015
- 2015-06-12 HK HK16114577.4A patent/HK1226389A1/zh unknown
-
2016
- 2016-09-14 US US15/265,549 patent/US20170066777A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013246485A1 (en) | 2014-10-16 |
| US9487535B2 (en) | 2016-11-08 |
| EA201491854A1 (ru) | 2015-03-31 |
| HK1205113A1 (en) | 2015-12-11 |
| JP2015516389A (ja) | 2015-06-11 |
| HK1226389A1 (zh) | 2017-09-29 |
| JP6195609B2 (ja) | 2017-09-13 |
| EP2838902B1 (en) | 2018-12-05 |
| WO2013154712A1 (en) | 2013-10-17 |
| ES2714314T3 (es) | 2019-05-28 |
| CN105753877A (zh) | 2016-07-13 |
| CA2869547A1 (en) | 2013-10-17 |
| IL235006A0 (en) | 2014-12-31 |
| ZA201407334B (en) | 2017-05-31 |
| KR20150002794A (ko) | 2015-01-07 |
| EP2838902A1 (en) | 2015-02-25 |
| US20130274483A1 (en) | 2013-10-17 |
| US20170066777A1 (en) | 2017-03-09 |
| MX2014012266A (es) | 2014-12-05 |
| CN104350057A (zh) | 2015-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1205114A1 (en) | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents | |
| TN2012000171A1 (en) | Synthetic methods for spiro-oxindole compounds | |
| WO2014031928A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
| WO2014031933A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
| MX362550B (es) | Inhibidores ciclicos de glutaminasa. | |
| MX2013004307A (es) | Derivados de arilamida como bloqueadores de ttx-s. | |
| MX2015005015A (es) | Inhibidores heteroarilo de pde4. | |
| WO2014031936A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
| WO2013134336A3 (en) | Inhibition of adaptor associated kinase 1 for the treatment of pain | |
| HK1220442A1 (zh) | Ido抑制剂 | |
| MY199131A (en) | Human plasma kallikrein inhibitors | |
| EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
| PH12013501600A1 (en) | Novel heterocyclic derivatives | |
| EA201400161A1 (ru) | Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов | |
| MX366308B (es) | Derivados de amida como bloqueadores de ttx-s. | |
| MY180751A (en) | 3,4-dihydroisoquinolin-2(1h)-yl compounds | |
| WO2013134353A8 (en) | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor | |
| MX360323B (es) | Derivados de pirrolopiridinona como bloqueadores de ttx-s. | |
| MX2012001134A (es) | Composiciones y metodos para inhibicion de la via jak. | |
| MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
| WO2011127048A3 (en) | NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE | |
| WO2014035846A3 (en) | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use | |
| MX2015005361A (es) | Derivados de pirazolopiridina como bloqueadores de ttx-s. | |
| PL392436A1 (pl) | Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego | |
| WO2014070971A3 (en) | Somatostatin-dopamine chimeric analogs |